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ADAM17 is a metalloprotease and disintegrin that lodges in the plasmatic membrane
of several cell types and is able to cleave a wide variety of cell surface proteins. It
is somatically expressed in mammalian organisms and its proteolytic action influences
several physiological and pathological processes. This review focuses on the structure
of ADAM17, its signaling in the cardiovascular system and its participation in certain
disorders involving the heart, blood vessels, and neural regulation of autonomic and
cardiovascular modulation.
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INTRODUCTION
A Disintegrin and Metalloproteases (ADAM), originally named metalloproteinases disintegrin
cystein-rich (MDC), are membrane-anchored cell surface proteins containing both disintegrin and
metalloproteinase domains. They belong to the adamalysin protein family in the zinc protease
superfamily and combine features of both proteases and cell surface adhesionmolecules (Wolfsberg
and White, 1996; Seals and Courtneidge, 2003). By 2010, 40 ADAM homologs had been identified
in the mammalian genome and 21 ADAM described, among which only 13 were proteolytically
active (Edwards et al., 2008). The ADAMs responsible for protein cleavage are called sheddases. It is
estimated that as much as 10% of the cell surface proteins undergo ectodomain shedding. Members
of the ADAM family contribute to various physiological and pathophysiological processes by
modulation of molecules like growth factors or cytokines. The prototype of ADAM with sheddase
activity is exemplified in ADAM17.
ADAM17 (EC 3.4.24.86), also known as tumor necrosis factor-α converting enzyme (TACE), is
a metallopeptidase which has extensive somatic distribution, being expressed significantly in the
heart, vessels, brain, kidney, testicle, placenta, ovary, lung, spleen, and skeletal muscle, with levels
varying from embryonic development to adulthood (Black et al., 1997; Patel et al., 1998; Sahin
et al., 2004; Dreymueller et al., 2012). ADAM17 was described for the first time by Black et al., as a
newmember of the family of mammalian adamalysins, to specifically cleave the precursor of tumor
necrosis factor α (pro-TNFα; Black et al., 1997;Moss et al., 1997). Until now, ADAM17was revealed
as the major sheddase, of which the substrates cover a diverse variety of membrane-anchored
cytokines, cell adhesion molecules, receptors, ligands, and enzymes, such as TNFα, transforming
growth factor α (TGFα), L-selectin, and angiotensin-converting enzyme type 2 (ACE2; Kishimoto
et al., 1989; Sahin et al., 2004; Weskamp et al., 2004; Lambert et al., 2005; Scheller et al., 2011).
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As predicted by the wide variety of ADAM17 substrates,
global disruption of the ADAM17 gene in vivo results in the
death of mice between embryonic day 17.5 and the first day
after birth, due to a number of developmental defects from
brain, heart, lung, skin, skeletal, and immune system (Peschon
et al., 1998; Jackson et al., 2003). In human, a few cases have
shown a rare syndrome, in which patients with a homozygous
mutation in ADAM17 present severe diarrhea, skin rashes and
recurrent sepsis, eventually leading to their early death (Bandsma
et al., 2015). On the other hand, due to the structural and
functional heterogeneity of ADAM17 substrates, the sheddase is
also involved in various pathological processes such as cancer,
inflammatory diseases, neurological diseases, cardiac failure,
atherosclerosis, diabetes, cardiac hypertrophy, and hypertension
(Sandgren et al., 1990; Black et al., 1997; Peschon et al., 1998; Li
et al., 2006; Ohtsu et al., 2006b; Zhan et al., 2007; Wang et al.,
2009; Scheller et al., 2011; Giricz et al., 2013;Menghini et al., 2013;
Xia et al., 2013).
In this review, we summarize the seemingly paradoxical
functions of ADAM17 with a particular emphasis on the
cardiovascular and central nervous systems (CNS). The structure
and structure-based modulation of ADAM17 are also described
for better understanding of the various ADAM17 regulatory
pathways in different cell types or tissues. Finally, we also discuss
the contribution of ADAM17 as a potential therapeutic target in
cardiovascular disorder and the neurogenic component of these
cardiovascular diseases.
ADAM17 STRUCTURE
ADAM17 has the structural characteristics of disintegrin and
metalloproteases proteins that exist predominantly in two forms:
as the full-length protein (∼100 kDa) and as a mature form
lacking the pro-domain (∼80 kDa; Gilles et al., 2003). As
shown in Figure 1, the full-length protein (or pro-ADAM17)
is composed of 824 amino acids and consists of a series of
conserved protein domains: an N-terminal signal sequence
(aa 1–17), followed by a pro-domain (aa 18–216), in which
there is a cysteine switch-like region (CysSL) PKVCGY186 (aa
181–188), a catalytic domain (aa 217–474) with a Zn-binding
domain region (Zn-BR) (aa 405–417), a disintegrin cysteine-
rich domain (aa 480–559), an EGF-like region (aa 571–602),
a transmembrane domain (aa 672–694), and a cytoplasmic
tail (aa 695–824). Tyr702, Thr735, Ser819 have been shown as
cytoplasmic phosphorylation (P) sites, Ser791 has been shown
as cytoplasmic desphosphorylation site (Patel et al., 1998; Ohtsu
et al., 2006a; Gooz, 2010; Xu and Derynck, 2010; Niu et al.,
2015).
The pro-domain of ADAM17 includes a cysteine switch box
(Galazka et al., 1996), which is an unpaired cysteine residue and
play a key role in the pro-domain release prior to ADAM17
activation (Van Wart and Birkedal-Hansen, 1990; Roghani et al.,
1999). Normally, the pro-domain of ADAM17 acts as an inhibitor
of the protease via linkage of a cysteine switch box (SH-group)
to the zinc atom in the active catalytic site. Removal of the pro-
domain is a pre-requisite for ADAM17 activation (Reiss and
Saftig, 2009). ADAM17 is synthesized and stored in the rough
endoplasmic reticulum, the pro-domain removal occurs in a
late Golgi compartment, most likely by furin or furin-like pro-
protein convertase or by autocatalysis, providing themature form
of ADAM17 (Adrain and Freeman, 2012; Dreymueller et al.,
2012). Data from Srour et al., using in vitro and in vivo cleavage
assays, highlight the pro-protein convertases PACE-4, PC5/PC6,
PC1, and PC2, as some examples of furin-like enzymes that
can directly cleave the ADAM17 protein (Srour et al., 2003).
After maturation, ADAM17 translocates to the cell surface to
perform proteolytic and non-proteolytic functions (Zhang et al.,
2016). Since the pro-domain is highly sensitive to proteolysis,
once detached from catalytic domain, it will be degraded rapidly,
preventing its re-association with this domain. It has also
been suggested that changes in conformation, mediated by the
cysteine-rich domain, result in reducing the affinity between pro-
and catalytic domains (Milla et al., 1999). Another function of the
pro-domain is to chaperone the proper folding of ADAM17 and
other ADAM (Loechel et al., 1999; Milla et al., 1999; Anders et al.,
2001; Leonard et al., 2005; Li et al., 2009).
The catalytic or metalloproteinase domain starts downstream
from the consensus furin cleavage site (RVKRR215) and contains
a canonical zinc-binding site and a consensus (HEXXH) motif,
crucial for the catalytic activity. It mediates shedding of
membrane-bound proteins (Maskos et al., 1998; Ohtsu et al.,
2006a).
The cysteine-rich domain of ADAM17 includes a disintegrin-
like region that can bind to integrins, therefore ADAM17 exhibit
both proteolytic and adhesive characteristics (Zhang et al., 2016).
Furthermore, Reddy et al. (2000) suggested that the cysteine-
rich domain might be involved in recognition of substrates.
Following the disintegrin domain, a single transmembrane
domain defines the end of the catalytic domain of ADAM17
and then followed by a cytosolic tail that contains consensus
sequences for binding to proteins containing Src homology 2 and
Src homology 3 domains. Little has been known about the role
of this domain in regulating catalytic activity and physiological
substrates recognition (Qi et al., 1999).
The role of the cytoplasmic domain in ectodomain shedding
still remains controversial. Fan et al. and Gechtman et al.
reported that the cytoplasmic domain of ADAM17 is involved in
the regulation of ectodomain cleavage in response to intracellular
signaling events such as receptor protein tyrosine kinase and
mitogen-activated protein kinases (MAPK) activation (Fan
and Derynck, 1999; Gechtman et al., 1999). Arguably, soluble
ADAM17 forms, lacking trans-membrane and cytoplasmic
domain, can cleave trans-membrane proteins or synthetic
peptide substrates but not very efficiently (Kahn et al.,
1998; Reddy et al., 2000; Fan et al., 2003; Gonzales et al.,
2004; Li and Fan, 2004). However, it was soon found that
the ADAM17 transmembrane domain proved to play a
critical role in appropriately regulating substrate recognition.
When the ADAM17 trans-membrane domain was switched
with the transmembrane domain of prolactin receptor
and platelet-derived growth factor receptor (PDGFR) it
strongly inhibit TGFα release, with no change in L-selectin
shedding. However, switching the transmembrane domain
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FIGURE 1 | Schematic representation of the structure of full-length ADAM17.
of TGFα with that of L-selectin actually restored cleavage
activity of the transmembrane switched ADAM17 (Li et al.,
2007).
POST-TRANSLATIONAL REGULATION OF
ADAM17
The fact that ADAM17 has a wide diversity of substrates raise the
questions about where, when, and how it is activated. Shedding
activity led by ADAM17 is sequestered in cholesterol micro-
domains within the cellular membrane. Cholesterol is often
found to be distributed non-randomly in domains or pools in
membranes, therefore these cholesterol-enriched microdomain,
also known as “lipid raft,” is thought to be an important micro-
environment, in which the signaling pathway can be regulated
specifically (Pucadyil and Chattopadhyay, 2006). Depletion of
membrane cholesterol by methyl-β-cyclodextrin can induce
ADAM17-dependent shedding (Tellier et al., 2006).
It was shown in an early report that ADAM17 cytoplasmic
domain was not critical for the phorbol-ester (PMA)-induced
TNFα shedding (Reddy et al., 2000). However, considering that
PMA is a strong and pleiotropic activator, this cytoplasmic
tail could still be necessary for stimulations working through
physiological signaling pathways. The cytoplasmic domain of
ADAM17, which contains putative phosphorylation sites, is
thought to be required for regulation of the metalloprotease
activity via several intracellular signals. Now the involvement
of MAPK in ADAM17 activation is well-accepted. So
far, two phosphorylation sites (Thr735, Ser819) and one
dephosphorylation site (Ser791) located on the cytoplasmic
tail have been recognized. Mutation or dephosphorylation on
Ser791 enhance ADAM17 phosphorylation at Thr735, which can
be decreased by mutation on Ser819 (Xu and Derynck, 2010).
Replacing Thr735 with alanine, which cannot be phosphorylated,
resulted in accumulation of non-functional ADAM17 on
the cell surface. Both extracellular signal-regulated kinase
(ERK) and p38-MAPK pathways activate ADAM17 through
Thr735 phosphorylation. In mammalian cells, ERK-mediated
phosphorylation of ADAM17 at Thr735 highlights a key step in
inducible ADAM17 protein trafficking and maturation (Soond
et al., 2005). Protein kinase C (PKC) used to be considered as
an upstream signal of ERK/MAPK pathway, however, it may
also have direct role in ADAM17 phosphorylation. A recent
study showed that the PKCδ inhibitor, rottlerin, significantly
inhibited both constitutive, and high glucose-induced ACE2
shedding, which is mediated by ADAM17, and treatment with
PKCδ-targeting siRNA reduced ACE2 shedding by ∼20% (Xiao
et al., 2016). Other protein kinases, such as protein kinase G
(PKG), phosphoinositide-dependent kinase 1 (PDK1), and
Polo-like kinase 2 (PLK2), were also involved in ADAM17
phosphorylation in various cell types (Zhang et al., 2006;
Chanthaphavong et al., 2012; Schwarz et al., 2014).
PMA can increase ADAM17 activity in multiple ways. An
early report suggested that PMA might activate ADAM17
through ROS generation in monocytic cell line (Zhang et al.,
2001). Actually, mutation of Thr735 had little effect on PMA-
stimulated ADAM17 activation. Therefore, other than being an
upstream signal of ERK/MAPK pathway, ROS may also have
a role in translocating mature ADAM17 from Golgi to the cell
surface. In p47phox KO mice, translocation of ADAM17 was
partially blunted in cardiomyocytes when the ROS production
pathway was blocked (Patel et al., 2014). In addition to ROS,
ADAM17-mediated ectodomain shedding can be stimulated
by calcium influx in a short term manner. Stimulation with
ionomycin (a calcium ionophore) rapidly increased the level
of interleukin-6 receptor (IL-6R) shedding in mice, however, it
is still unclear whether other ADAM might contribute to this
process (Garbers et al., 2011).
Though cytoplasmic phosphorylation is not required for
PMA-induced ADAM17 activation, the presence of iRhom2
(inactive rhomboid type 2) was found to be indispensable.
Actually, both iRhom1 and iRhom2 are involved in the
maturation of ADAM17, and they can compensate each other’s
function in most of tissues except for the brain and immune
system (Maretzky et al., 2013; Li et al., 2015). iRhom1/2
regulate forward trafficking of ADAM17 from endoplasmic
reticulum (ER) to Golgi compartment where the pro-domain of
ADAM17 can be cleaved (Adrain and Freeman, 2012). However,
the underlying mechanism of this phenomenon remains
unknown.
ADAM17-MEDIATED SIGNALING IN
DEVELOPMENTAL PROCESS
Notch Signaling
ADAM-mediated shedding of Notch receptor is a key step in
activating Notch signaling. The Notch receptor and its ligand
Delta-l1 are required for neuroepithelial development during
embryogenesis (Wakamatsu et al., 1999; De Bellard et al., 2002).
The Notch signaling network is an evolutionarily conserved
intercellular signaling pathway that regulates interactions
between physically adjacent cells. In the brain, Notch1 promotes
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differentiation of progenitor cells into astroglia and knocking-
out the Notch1 gene is lethal at birth (Miller and Gauthier,
2007). Notch receptor is activated by one of five ligands: Jagged1,
Jagged2, Delta-l (like) 1, Delta-l3, or Delta-l4, expressed on
adjacent cells. Following ligand binding, Notch receptor is
cleaved by ADAM17 at site 2 (S2) and then by γ-secretase at site
3 (S3) (Kopan and Ilagan, 2009), and so is the ectodomain release
of Delta and Jagged (Murthy et al., 2012; Groot et al., 2013).
Both murine Notch1 and Notch2 require ADAM17 instead
of ADAM10 during ligand-independent activation, which is
resisted by the human Notch2 (Habets et al., 2015). Since
there are major cardiovascular defects in the ADAM17 global
knockout mice, which failed to survive postnatal, ADAM17
would also play a role in vascular physiology. In the adult
epidermis, ADAM17 permits tonic Notch activation to regulate
epithelial cytokine production and maintain barrier immunity.
During cerebral angiogenesis, Notch signaling is initiated by
receptor-ligand recognition between adjacent cells (Serra et al.,
2015). Overexpression of ADAM17 can promote angiogenesis by
increasing blood vessel sprouting and pericytes number during
brain micro vessel development (Lin et al., 2011).
EGFR Signaling
Within the cardiovascular system, Shi et al. (2003) demonstrated
that ADAM17 possibly regulates cardiomyocyte proliferation
during the late fetal stage of cardiac development via an
epithelial growth factor receptor (EGFR)-mediated pathway.
It was showing in the ADAM17 global knockout mice,
a remarkably enlarged heart with increased myocardial
trabeculation and reduced cell compaction (Shi et al., 2003). It
has also been reported that mice lacking functional ADAM17
suffer from several cardiac abnormalities in valvulogenesis,
such as thickened, deformed semilunar, and atrioventricular
valves (Jackson et al., 2003). Importantly, these lethal cardiac
abnormalities resulted from insufficient EGFR activation, which
were due to the lack of ADAM17 (Blobel, 2005). The up-
regulation of EGFR by ADAM17 stems from the critical ability
of this metalloprotease to cleave multiple EGFR ligands, such as
EGF itself, TGFα; epiregulin; heparin binding EGF-like growth
factor (HB-EGF), and neuregulins β1 and β2 (Peschon et al.,
1998; Merlos-Suárez et al., 2001; Hinkle et al., 2004; Sahin et al.,
2004; Horiuchi et al., 2005; Saftig and Reiss, 2011). Neuregulins
β1/2 are considered to be critical to cardiac development (Meyer
and Birchmeier, 1995; Meyer et al., 1997; Britsch et al., 1998).
Arguing against potential compensatory or redundant functions
of other members from the ADAM family, quadruple knockout
mice lacking ADAM 9, 12, 15, and 17 do not have a more severe
phenotype than mice lacking only ADAM17 (Sahin et al., 2004).
In addition to the defects on cardiac development, removal of
ADAM17 from subcortical white matter (SCWM) of postnatal
mice (90 days) led to abnormalities in Schwann myelination
causing impaired motor behaviors (Palazuelos et al., 2014).
ADAM17-induced shedding of EGFR ligands, HB-EGF and
TGFα, promotes the expansion of oligodendrocyte progenitor
cells during the critical periods of Schwann myelination.
However, neuregulin-1 cleavage mediated by ADAM17 can
negatively regulate myelination in the peripheral nervous system.
Down-regulation of ADAM17 expression or its inactivation in
motor neurons can lead to abnormalmyelination (LaMarca et al.,
2011).
ADAM17-MEDIATED CYTOKINES AND
ADHESION MOLECULES SIGNALING
In the Heart
Soluble TNFα, a potent cytokine, is converted from pro-TNFα
through ADAM17-mediated cleavage in various cell types. In
heart, TNFα is crucially involved in the genesis and progression
of several cardiovascular processes. Satoh et al. (1999) have
shown that myocardial ADAM17 and TNFα expression in both
mRNA and protein levels are increased in humans with dilated
cardiomyopathy (Satoh et al., 1999), establishing a positive
correlation between ADAM17 and TNFα in cardiovascular
disorder. They later showed that increased expression of
TNFα and ADAM17 had important implications in advanced
cardiac dysfunction in myocarditis. In the myocardium, TNFα
contributes to reversible and irreversible ischemia/reperfusion
injury, post myocardial infarction remodeling, and heart failure
development. Simultaneously, TNFα is also involved in cardio-
protective processes in ischemic conditioning. The harmful and
beneficial roles of TNFα appear to be dose- and time-dependent
and in part related to the activation of specific receptor subtypes
(Kleinbongard et al., 2010).
One possible pathway to activate TNFα in the myocardium is
through EGFR and many studies have shown that ADAM17 is
the main contributor to EGFR transactivation in cardiovascular
system (Ohtsu et al., 2006b; Takayanagi et al., 2015).
Furthermore, Küper et al. (2007) were the first to suggest a
co-dependency between ADAM17-mediated up-regulation of
EGFR and TNFα. They observed that within renal collecting duct
cells LPS induces EGFR activation via TLR4/ADAM17 (Küper
et al., 2007). Based on this study, Sun et al. (2015) have found
that this promotes myocardial TNFα production and cardiac
failure in endotoxemic mice (Sun et al., 2015). Another TNF-α
activation pathway in cardiac cells by ADAM17 is through
the non-receptor tyrosine kinase, Src. Src mediates ADAM17
activation in mechanically stretched rat cardiomyocytes by
phosphorylating the Tyr702 residue within the intracellular tail of
ADAM17, leading to activation of p38 MAPK and thus TNF-α
receptor activation (Niu et al., 2015).
The association between ADAM17 and cardiac function is
not limited to local effects in the heart. Akatsu et al. (2003)
demonstrated an increased expression of TNFα and ADAM17
in circulating leukocytes of patients with acute myocardial
infarction (AMI) associated with higher plasma TNFα levels
when compared with healthy control patients (Akatsu et al.,
2003). Shimoda et al. (2005) confirmed the positive correlation
between ADAM17 and TNFα levels in AMI (Shimoda et al.,
2005). In addition, they observed that these levels were higher
in peripheral blood mononuclear cells from AMI patients with
in-hospital complications, such as pump failure, malignant
ventricular arrhythmia, recurrent myocardial infarction, and
cardiac death. Moreover, ADAM17 expression and TNFα levels
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were found to be increased in peripheral blood mononuclear
cells, especially from individuals with advanced congestive heart
failure (Satoh et al., 2004).
In the Vasculature
ADAM17 expression is found throughout endothelial cells,
smooth muscle cells, fibroblasts, and leukocytes (Dreymueller
et al., 2012). The consequences of shedding events for vascular
biology depend on the type of substrate shed. This can
result in pro- or anti-inflammatory effects depending on the
nature of the transmembrane protein cleaved, the generation
of soluble receptor agonists or antagonists, modulation of
cellular responsiveness, modulation of adhesive properties,
and formation of transcription factors (Canault et al., 2006).
Interestingly, ADAM17 has been described to be overexpressed
in ruptured coronary plaques from infarcted patients and
atherosclerotic plaques from apolipoprotein E knockout mice
(apoE−/−, an important experimental model of atherosclerosis;
Canault et al., 2006; Satoh et al., 2008), revealing its fundamental
role in this vascular disease.
ADAM17 activity is correlated to adverse clinical outcomes
in acute coronary atherosclerosis (Satoh et al., 2008; Gutiérrez-
López et al., 2011; Rizza et al., 2015). An important group of
substrates for ADAM17 includes adhesion molecules such as
ICAM-1 (intercellular adhesion molecule-1), VCAM-1 (vascular
cell adhesion molecule-1), L-selectin, and others. These adhesion
molecules are involved in leukocyte migration through the vessel
wall which is one of the first steps leading to atheroma formation
(Gutiérrez-López et al., 2011; Freitas Lima et al., 2015). Shedding
of cell adhesion molecules weakens cell–cell interactions and
reduces adhesiveness of leukocytes (Arribas and Esselens, 2009;
Dreymueller et al., 2012). It has been reported that ADAM17
null leukocytes present increase L-selectin levels (Tang et al.,
2011). Interestingly, Zhang et al. demonstrated that nitric oxide
(NO) is a critical factor involved in ADAM17 activation due to
nitrosilation of thiol group in cysteine residues in the inhibitory
pro-domain of ADAM17. This might explain the increased
adhesion of leukocytes in dysfunctional endothelium (Zhang
et al., 2000), which presents reduced NO bioavailability (Balarini
et al., 2013).
In the Central Nervous System
Kärkkäinen et al. (2000) was the first to demonstrate the
expression of ADAM17 mRNAs in adult mouse and rat brains,
using in situ hybridization (Kärkkäinen et al., 2000). ADAM17
showed a restricted pattern of distribution in the telencephalon
and diencephalon. Within the mesencephalon, ADAM17 mRNA
was detected in the hippocampus along with the inferior
colliculus. In addition, ADAM17 mRNA was also detected in the
cerebellar cortex, pontine nuclei, and cerebral cortex. According
to these data, Hurtado et al. (2001) demonstrated constitutive
expression of ADAM17 protein in rat brain (Hurtado et al., 2001).
Aspects related to cell location and origin of ADAM17 have been
clarified in later studies.
Goddard et al. (2001) in an immunohistochemical study
showed that ADAM17 is expressed in astrocytes and endothelial
cells from healthy adult human brain tissue and may have a role
in normal brain function (Goddard et al., 2001). Hurtado et al.
(2002) also found ADAM17 protein expression in astrocytes as
well as rat microglial cells (Hurtado et al., 2002). Skovronsky et al.
(2001), using Western Blots and immunolabeling approaches,
found that ADAM17was present in neurons of the hippocampus,
cortex and cerebellum, and was slightly detectable in astrocytes,
oligodendrocytes, and microglial cells (Skovronsky et al., 2001).
Since ADAM17 is expressed in different cell types in the CNS and
promotes ectodomain shedding of several molecules, this enzyme
would participate in several cellular events.
Increased plasma ADAM17 activity was found in patients
with mild cognitive impairment. Within the brain, ADAM17
can work as an α-secretase and cleave the amyloid precursor
protein (APP) into soluble APPα fragment (sAPPα; Skovronsky
et al., 2001; Asai et al., 2003). This shedding of APP is able to
reduce the generation of neurotoxic amyloid β (Aβ) peptide in a
competitive way. It is believed to be a possible neural protection
and repair mechanism. On the contrary, ADAM17 is also a
neuro-inflammatory target which responds to ischemia and other
stress factors (Romera et al., 2004; Munhoz et al., 2008). Some
of the subsequently increased inflammatory factors, like TNFα,
can activate glial cells and be harmful to homeostasis within the
brain (Suzumura, 2013). From this point of view, activation of
ADAM17 can be neurotoxic. As described before, ADAM17 was
initially reported to be responsible for the proteolytic activation
of the membrane precursor of TNFα, which is critically involved
in inflammation. The pro-inflammatory activity of TNFα is
predominantly mediated by TNFα receptor type 1 (TNFR1)
and to some extent by TNF receptor type 2 (TNFR2), both
of which have been found to undergo shedding via ADAM17
(Chanthaphavong et al., 2012). Wang et al. (2003) had linked
the shedding of TNF receptors to neutralization of soluble
TNFα-induced actions. Either ADAM17 expression or activity
have found to be altered in neuro-inflammatory conditions, in
which, the level of TNFα is increased, such as stroke, multiple
sclerosis, or traumatic brain injury (Romera et al., 2004; Plumb
et al., 2006). Conditional deletion of the ADAM17 gene or
inhibition of the protein, effectively blocks LPS-induced TNFα
release and systemic inflammation in mice (Zhang et al., 2004).
This demonstrates that ADAM17-mediated shedding is a critical
trigger for pro-inflammatory signaling of TNFα. In addition,
BB1101, a blocker of ADAM17, was shown to be effective
in reducing TNFα levels in stressed animal models (Madrigal
et al., 2002). Interestingly, the specific antagonist of NMDA
receptor, MK-801, can, not only decrease stress-induced activity
and expression of ADAM17, but also its constitutive expression,
as well as TNFα levels (Madrigal et al., 2002). Therefore, in
the CNS, excitation or stimulations targeting glutamatergic
neurons may cause up-regulation of ADAM17 activity and will
contribute to neuro-inflammation eventually. The mechanism
of this neuro-excitation-induced ADAM17 activation is thought
to be mediated via nuclear factor-κ B (NFκB). Stress-induced
neuro-inflammation activates NFκB in the hippocampus as
soon as 4 h after the onset of stress in rats (Madrigal et al.,
2006). The implication of ADAM17 and TNFα in stress-
induced activation of NFκB was confirmed after finding that
decreased TNFα is mediated by hepatocyte growth factor-like
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protein-induced decrease in NFκB activation and increased by
the NFκB inhibitory protein, IκB (Nikolaidis et al., 2010).
Besides TNFα, inflammation is also characterized by elevated
levels of interleukin-6 (IL-6). ADAM17 is the main sheddase
for IL-6 receptor (IL-6R) to induce IL-6 trans-signaling
(Pruessmeyer and Ludwig, 2009). Released IL-6R is capable
of binding IL-6 and the formed receptor-ligand complex then
stimulates gp130 on the cell surface, even in the absence of
transmembrane IL-6R (Scheller et al., 2011). This pathway is
thought to play an important role in chronic inflammatory
processes. In immune cells, like neutrophils, ADAM17 and
secondary shedding of IL-6R can be activated by apoptosis
(Chalaris et al., 2007).
In the nervous system, expression of cell adhesion molecules
(CAMs) can be up-regulated by glia-secreted cytokines.
Shedding of the CAMs, such as CX3CL1 (fractalkine),
L-selectin, VCAM-1, and JAM-A (junctional adhesion
molecule-A) are induced by activation of ADAM10 or
ADAM17 (Kalus et al., 2006; Pruessmeyer and Ludwig,
2009). In the periphery, CX3CL1 guides leukocytes to the
site of inflammation. Within 4–6 h after onset of ischemia,
circulating leukocytes adhere to vessel walls and migrate
into the brain with subsequent release of additional pro-
inflammatory mediators. The ADAM17-related adhesion
procedure is critical during the process of inflammation
(Lakhan et al., 2009). On the other hand, CX3CL1 can be
secreted from damaged neurons and then activate microglia to
rescue neurons by up-regulating phagocytosis of toxicants or
damaged debris and production of anti-oxidant enzymes, like
superoxide dismutase (Vernon and Tang, 2013; Limatola and
Ransohoff, 2014). Furthermore, ADAM17-mediated shedding
is important to neuronal outgrowth in the developmental
process. ADAM17 regulates L1CAM (L1-cell adhesion
molecule)-dependent neuronal cell adhesion, cell migration,
as well as neurite outgrowth (Mechtersheimer et al., 2001;
Maretzky et al., 2005). L1CAM has been observed within
late embryonic/early postnatal cortical neurons and fibers in
the corpus callosum and corticospinal tract (Fujimori et al.,
2000; Jakovcevski et al., 2013). In mice embryonic cortex,
knocking-down ADAM17 could affect L1-involed neuronal
intermediate progenitor cells multipolar exit and migration
(Li et al., 2013).
ADAM17-MEDIATED GROWTH FACTORS
SIGNALING
In Vascular Remodeling and Formation of
Atherosclerotic Plaques
ADAM17 is expressed in atherosclerosis-prone sites, however
it is not clear whether this expression is due to an up-
regulation of enzyme expression or due to its expression by
newly infiltrated vascular smooth muscle cells (VSMCs) and
leukocytes (Canault et al., 2006). It is well-established that Ang-
II can induce VSMC hypertrophy, proliferation and migration,
which are important steps toward atheroma formation (Freitas
Lima et al., 2015). Ang-II can induce ADAM17 protein
expression in the vasculature and increase its activity by
tyrosine phosphorylation (Elliott et al., 2013; Obama et al.,
2015). ADAM17-induced EGFR transactivation is considered
a major contributor in Ang-II-induced vascular remodeling.
It was reported that Ang-II induces expression of fibronectin
and transforming growth factor-β (TGFβ) through downstream
signaling of EGFR transactivation and ER stress. This occurs via
a signaling mechanism involving ADAM17-mediated shedding
which is independent of hypertension (Moriguchi et al., 1999;
Takayanagi et al., 2015).
In atherosclerotic plaques, neovascularization occurs as a
physiological response to increased oxygen demand which
causes adverse effects by facilitating inflammatory influx and
favoring the conditions that destabilize the plaque. Thus,
inhibition of neovascularization results in limited atherosclerotic
lesion (van Hinsbergh et al., 2015). ADAM17 positively
regulates angiogenesis by inhibiting the expression of the anti-
angiogenic factor thrombospondin 1, presenting a positive role
in pathological angiogenesis (Caolo et al., 2015). ADAM17 is
also critical for EGFR signaling due to the proteolytic release
of several ligands of EGFR in the vessels, such as HB-EGF.
Weskamp et al. demonstrated that inactivation of ADAM17
in endothelial cells reduced pathological neovascularization
whereas its inactivation in smooth muscle cells revealed no
evident effect (Weskamp et al., 2010). The underlyingmechanism
is probably EGFR signaling stimulated by EGFR ligands released
by ADAM17 from endothelial cells. Selective inhibition of
ADAM17 could be beneficial for the treatment of diseases
implied in pathological neovascularization (Weskamp et al.,
2010), such as atherosclerosis. Vascular endothelial growth
factor (VEGF-A) and its receptor (VEGFR) are also critical
for regulating angiogenesis in physiological and pathological
conditions. VEGFR type 2 is a tyrosine kinase receptor which
is considered the principal coordinator of adult angiogenesis
(Swendeman et al., 2008). This receptor can be shed from cells by
ADAM17. VEGF-A/VEGFR2were shown to stimulate ADAM17,
resulting in shedding of VEGFR2 and other ADAM17 substrates
(Swendeman et al., 2008). This could limit angiogenesis process
and reveal a potential novel target for treatment of pathological
neovascularization associated to atherosclerosis. It is important
to highlight that ADAM17 over-expression or inhibition could
either increase or decrease neovascularization as it also presents
pro- or anti-inflammatory functions.
Plaque rupture and subsequent thrombotic complications
are adverse events associated with atherosclerosis (Freitas Lima
et al., 2015). Local over-activity of ADAM17 may weaken
atherosclerotic plaques, causing its rupture. In this context,
Rizza et al. suggested that measuring ADAM17 activity may
predict major cardiovascular events in subjects with established
atherosclerosis (Rizza et al., 2015). Although ADAM17 activity
was evaluated in an indirect manner through themeasurement of
its substrates in circulation, authors suggest that it is reasonable
to assume that the increase in these molecules is related to
increased ADAM17 activity in inflammatory sites. In addition,
it was observed that unsaturated fatty acids in LDL particles
are also involved in ADAM17 activation in the endothelial
layer, due to increase in membrane fluidity, creating a link
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between endothelial dysfunction/atherosclerosis and increase
in ADAM17 substrates in patients at risk (Reiss et al., 2011;
Menghini et al., 2013).
In Brain Injury and Tumor
Over the years, an important role for ADAM17 in neural injury
and degeneration has gradually become clear. Via shedding
of TGFα, ADAM17 can work as the constitutive sheddase of
epiregulin and amphiregulin, both members of the epidermal
growth factor (EGF) family playing important roles in the
regulation of cell growth, proliferation, and survival (Freimann
et al., 2004; West et al., 2008). Recombination of epiregulin
and amphiregulin proteins can effectively inhibit endoplasmic
reticulum stress and the subsequent induction of neuronal cell
death. Therefore, up-regulation of epiregulin and amphiregulin
in glial cells may have neuro-protective effects and provide a
potential therapy for brain injury (Zhan et al., 2015). However,
there is evidence suggesting an association between increased
expression of ADAM17 and various types of cancer. EGFR
binding with ligands after ADAM17-induced shedding can
subsequently activate MEK/ERK and PI3K/Akt pathways, which
contribute to the invasiveness and other malignant phenotypes
of tumors. Glioma is the most common malignant intrinsic
primary brain tumor. By up-regulating the ligands of EGFR,
ADAM17 can promote glioma cells malignant phenotype by
increased proliferation, invasion, and angiogenesis. In glioma
cells and glioma-bearing nude mice, targeting ADAM17 with
TAPI-2 (an ADAM17 inhibitor) or siRNA, can significantly
attenuate tumor growth and invasiveness, compared to their
untreated counterparts (Zheng et al., 2012). Further, it has been
shown that beyond the EGFR pathway, TGFβ (transforming
growth factor-β) also plays a key role in the regulation of
glioma formation and progression (Lu et al., 2011). Interestingly,
TGFβ, which can rapidly induce ADAM17 phosphorylation, is
actually an upstream signal of ADAM17 (Wang et al., 2008).
However, the mechanism of TGFβ-induced tumor formation
and progression is not simply mediated by activation of the
downstream EGFR pathway. Mu et al. found that TGFβ utilized
TRAF6 (TNFR-associated factor 6), PKC ζ and ADAM17 to
promote the formation of the TβRI (serine/threonine kinase
receptor I) intracellular domain, which could be translocated to
the nucleus, where it promotes tumor invasion by induction of
Snail and MMP2 (matrix metalloproteinase-2; Mu et al., 2011).
ADAM17-MEDIATED ACE2 SHEDDING
In the Cardiac Renin Angiotensin-System
(RAS)
Overactivity of the RAS contributes to the development and
maintenance of cardiac hypertrophy in experimental models and
humans. Whilst the primary physiological role of angiotensin-
converting enzyme (ACE) in the RAS is to hydrolyze Ang-I into
the potent vasoconstrictor Ang-II, ACE2 is able to cleave Ang-
II to produce Ang-(1–7), a peptide which has opposing effects
(Xia and Lazartigues, 2008). Therefore, ACE2 is an important
regulator within the RAS. Cardiac hypertrophy and impaired
contractility are associated with decreased ACE2, whereas ACE2
over-expression protects the heart from Ang II-mediated cardiac
hypertrophy and myocardial fibrosis (Bodiga et al., 2011; Patel
et al., 2012). Interestingly, neuronal overexpression of ACE2 has
also therapeutic effects on Ang-II-induced cardiac hypertrophy
(Feng et al., 2012), confirming the pivotal role of ACE2 within
the brain RAS and in the central regulation of cardiovascular
function. The compensatory role of ACE2 is compromised, as it is
a subject of ADAM17-mediated shedding. The ACE2 ectodomain
is cleaved from the cell membrane by ADAM17 and released into
the extracellular milieu (Lambert et al., 2005). This further fuels
the involvement of ADAM17 in cardiac hypertrophy, as has been
shown in both animal and human studies. For example, systemic
treatment of ADAM17-targeting siRNA for 30 days effectively
stopped the progression of agonist-induced cardiac hypertrophy
and fibrosis in adult spontaneously hypertensive rats and mice
following Ang-II infusion (Wang et al., 2009).
Similarly, Patel et al. (2014) found that in mice infused
with Ang-II, there was an angiotensin receptors type I (AT1R)-
mediated increase in myocardial ADAM17 expression and
activity. Membrane translocation of ADAM17 was linked
to a substantial reduction in myocardial ACE2 protein and
activity with a corresponding increase in plasma ACE2 activity,
suggesting that Ang-II-induced ACE2 shedding was mediated
by ADAM17. Reactive oxygen species seem to play a key
role since p47phox knockout mice were resistant to Ang-II-
induced ADAM17 activation with preservation of myocardial
ACE2 and attenuated Ang-II-mediated cardiac dysfunction and
hypertrophy (Patel et al., 2014).
In the Brain RAS
Lautrette et al. (2005) demonstrated that peripheral inhibition of
ADAM17 with TAPI-2 does not decrease systolic blood pressure
in Ang II-infused mice, suggesting that cardiac ADAM17
participates in the development of cardiac hypertrophy, but does
not play a primary role in the regulation of blood pressure
in this model (Lautrette et al., 2005). However, our group
has recently demonstrated that ADAM17 in the brain actually
contributes to the development of neurogenic hypertension
(Xia et al., 2013). Similar to the heart, overactivity of the
brain RAS is a major contributor to the development and
maintenance of neurogenic hypertension (Itaya et al., 1986;
Davisson et al., 1998). Deoxycorticosterone acetate (DOCA)-
salt treatment, a well-characterized model for neurogenic
hypertension (Yemane et al., 2010), led to enhanced ADAM17
expression and activity. This ultimately reduced the expression
and activity of ACE2 in the mouse hypothalamus (Xia et al.,
2013). In addition, the treatment with tempol or α-lipoic acid,
blunted ADAM17 activity and preserved ACE2 compensatory
effects, suggesting a possible role of oxidative stress in the
up-regulation of ADAM17 during DOCA-salt hypertension
(de Queiroz et al., 2015).
The activation of ADAM17 by DOCA-salt treatment could
be dependent on AT1R. Following AT1R activation, downstream
signaling pathways involving ROS, PKC, MAPK, and calcium
(Ca2+) might not only up-regulate the activity of ADAM17 but
also interfere with the protective effects of ACE2 by interacting
with other molecules. In ACE2-expressed HEK cells, calmodulin
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(CaM) interacts with ACE2. Inhibiting CaM increased the release
of the ACE2 ectodomain in a dose- and time-dependent manner
(Lambert et al., 2008). This association between CaM and ACE2
has also been reported in the CNS. In mice with DOCA-salt
hypertension, interaction between ACE2 and CaM was found to
be decreased (Xia et al., 2013), covceivably because of an increase
in intracellular [Ca2+]. The structure of CaM can be expanded
by its specific Ca2+ binding sites, which possibly contributes
to the dissociation of CaM from the cytoplasmic site of ACE2.
This might render ACE2 vulnerable to the shedding activity of
ADAM17.
The balance between the classic RAS and the ACE2-related
compensatory axis is important to the maintenance of a normal
blood pressure as well as central regulation of autonomic
function. In mouse basolateral amygdala, overexpression of
ACE2 significantly increased the frequency of spontaneous
inhibitory postsynaptic currents (indicative of presynaptic release
of GABA) from pyramidal neurons. This effect was eliminated
by central administration of a Mas receptor (MasR) antagonist,
suggesting a possible role of ACE2 in GABA neurotransmission
via MasR activation (Wang et al., 2016). Accordingly, ADAM17
can contribute to increased sympathetic outflow by down-
regulating ACE2 activity, which in turn exacerbates the
contribution of classic RAS. In mice with ACE2 deletion, we
observed an increase of baseline blood pressure, which could
reach hypertensive levels with age (Xia et al., 2011).
Moreover, ADAM17 can control the transcription of
matrix metalloproteinase-2 (MMP-2), which in turn mediated
angiotensin-II (Ang-II)-induced hypertension in mice
independently of cardiac hypertrophy or fibrosis, showing
that the effects of ADAM17 in the cardiovascular system may be
connected to other metalloproteinases (Odenbach et al., 2011).
The Figure 2 summarizes the main targets of ADAM17-
induced shedding described in the text, the downstream events
of their proteolytic cleavage and pathological and physiological
processes influenced by ADAM17-dependent shedding.
ADAM17 AS A THERAPEUTIC TARGET
A Brief Introduction of Endogenous
ADAM17 Inhibitor
ADAM share characteristics with the wider family of matrix
metalloproteinases (MMP), which are regulated by a group
of endogenous inhibitors. Among them, tissue inhibitors of
metalloproteinase 3 (TIMP3) not only blocks the activity of
MMP but also inhibits the ectodomain shedding induced by
ADAM17 (Amour et al., 1998). Both ADAM17 and TIMP3
have high abundance in the heart, kidney and brain. Mice with
TIMP3 deficiency show significant increase in ADAM17 activity
and soluble TNF-α abundance (Federici et al., 2005; Guinea-
Viniegra et al., 2009). This is believed to be responsible for Ang-
II-induced vascular inflammation and remodeling (Basu et al.,
2012, 2013). Zheng et al. (2016) demonstrated that enhanced
ADAM17 expression with decreased TIMP3 and increased TNF-
α expression, within 1 week after AMI, are associated with
cardiac remodeling (Zheng et al., 2016). These data confirm that
ADAM17 is an important regulator of TNF-α maturation and
may be a potential target for the inhibition of cellular TNF-
α production in cardiovascular disorders. In addition, it was
demonstrated that an imbalance between ADAM17 and TIMP3
is characteristic of unstable carotid plaques (Menghini et al.,
2013; Rizza et al., 2015). On the other hand, treatment with
soluble TIMP3 can impart a neuro-protective effect and enhance
neurite out-growth both in vitro and in animals with brain-
injury, in vivo by activating the Akt-mTORC1 signaling pathway
(Gibb et al., 2015).
In normal baseline conditions, the cytoplasmic tail of
ADAM17 supports cell surface homo-dimerization. The
ADAM17 homodimers associate with TIMP3, which silences
the shedding activity of ADAM17. Phosphorylation on the
cytoplasmic domain of ADAM17 disrupts the homodimers into
monomers. This relieves TIMP3 association from ADAM17
enabling it to increase proteolysis of its substrates and hence
shifting away from normal baseline condition (Xu et al., 2012).
Existing Knockout Models
Because of its essential role in normal fetal development,
disruption of the ADAM17 gene leads to perinatal lethality with
opened eyes, defects in aortic, pulmonic, and tricuspid heart
valves (Li et al., 2015). Mice with a targeted deletion of exon11
that encodes the catalytic active site of the metalloprotease
domain (adam171Zn/1Zn), resulting in a lack of enzymatic
activity, also display substantial perinatal lethality within 2 weeks.
Though one study reported that some adam171Zn/1Zn null
mice could survive to adulthood, they still have phenotypic
abnormalities like dramatic weight loss and significant defects
in the immune system (Gelling et al., 2008). Therefore, while
the global knockout model may be useful for studies focusing
on the physiological role of ADAM17, it might not be suitable
for investigating its therapeutic role in pathological processes.
Moreover, ADAM17-mediated shedding involves a variety of
receptors and substrates, which are distributed in different
cell types and various tissues. Accordingly, targeting of a
specific cell population or tissue becomes a better solution
for studies trying to identify ADAM17 and its potential
role in certain disease or pathological processes. Since the
therapeutic use of pharmacological inhibitors of ADAM17 also
has its own limitation, several types of conditional ADAM17
knockout animals have been generated and already expanded
our knowledge of ADAM17 roles (Table 1). Using Cre-LoxP
technology, these models are amenable for conditional, pre-
or post-developmental, deletion of neuronal ADAM17, making
them attractive for in vivo studies in adult animals devoid of
gross anatomical defects. These ADAM17 conditional knockout
models should be quite useful for studies focusing on ADAM17-
related neurological diseases and neurogenic cardiovascular
disorders.
CONCLUSION
ADAM17 has more than 70 different substrates, including
cytokines, growth factors, receptors, adhesion molecules,
and other proteins. There has been substantial progress in
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FIGURE 2 | Summary of targets of the shedding induced by ADAM17, subsequent effects in the cell signaling and events influenced by proteolytical
cleavage in the cardiovascular and nervous systems. ACE2, angiotensin-converting enzyme type 2; CX3CL1, fractalkine; EGFR, epithelial growth factor
receptor; HB-EGF, EGF-like growth factor; ICAM-1, intercellular adhesion molecule-1; IL-6, interleukin-6; JAM-A, junctional adhesion molecule-A; L1CAM, L1-cell
adhesion molecule; RAS, Renin Angiotensin-System; TGFα, transforming growth factor α; TNFα, tumor necrosis factor α; VCAM-1, vascular cell adhesion molecule-1;
VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
TABLE 1 | Summary of ADAM17 conditional knockout mice.
Mouse Targeted cell type and major phenotype References
Adam17flox/flox-Mx1Cre This inducible Cre can help create ADAM17 global KO at any time of
development; low response to LPS stimulation; low TNFα production;
improved energy homestasis
Horiuchi et al., 2007a; Kaneko et al., 2011
Adam17flox/flox-LysMCre Myeloid cell lineage (monocytes, mature macrophages and
granulocytes); reduced proinflammatory cytokines secretion
Horiuchi et al., 2007b
Adam17flox/flox-Sox9Cre Most tissues except for spleen and thymus; early death, phenotypes
are similar to global KO mice
Horiuchi et al., 2009
Adam17flox/flox-Tie2Cre Endothelial cells; reduced pathological neovascularisation and growth
of heterotopically injected tumor; developmental defects in heart valves
Weskamp et al., 2010; Wilson et al., 2013
Adam17flox/flox-HB9Cre Motor neurons; increased Schwann cell myelination La Marca et al., 2011
Adam17flox/flox-Foxn1Cre T cells, no effect on T cell development Gravano et al., 2010
Adam17flox/flox-Vav1Cre Hematopoietic cells (and their progenitors); reduced proinflammatory
cytokines release; faster neutrophil recruitment
Long et al., 2010; Arndt et al., 2011
Adam17flox/flox-TaglnCre Vascular smooth muscle cells; no effect on normal vascular
development
Weskamp et al., 2010
Adam17flox/flox-Krt14Cre Keratinocyte cells; normal at birth but develop defects in epidermal
barrier soon after birth; develop chronic dermatitis as adults
Franzke et al., 2012
understanding how ADAM17 mediates a range of physiological
functions and how ADAM17 mediates signaling pathway
contributing to the pathological processes in a variety
of neurological and cardiovascular disorders. Despite a
plethora of data in various fields, the role of ADAM17 in the
central regulation of cardiovascular modulation and related
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cardiovascular diseases is far from being elucidated. Although
there has been slow progress in translating the knowledge of
ADAM17 into possible new treatments, because of the diversity
of its substrates, it remains that ADAM17 could be used as
potential novel target for the treatment of cardiovascular
diseases. However, this will require treatment strategies with
improved efficiency and specificity.
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